EUVIMEDEUVIMED entdecken
Crossref

Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors

Lulu Zhang, Siqi Zhang, Jiang Wu, Yanrong Wang, Yuxuan Wu, Xiaona Sun, Xingkai Wang, Jieting Shen, Lin Xie, Yiding Zhang, Hailong Zhang, Kuan Hu iD und 3 weitere

Molecular Pharmaceutics · 2023

DOI: 10.1021/acs.molpharmaceut.3c00382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Lulu Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210008, China. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Melanoma. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Chinese Academy of Medical Sciences, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Programmed cell death receptor 1 (PD-1) and its ligand PD-L1 are particularly interesting immune checkpoint proteins for human cancer treatment. Positron emission tomography (PET) imaging allows for the dynamic monitoring of PD-L1 status during tumor progression, thus informing patients' response index. Herein, we report the synthesis of two linear peptide-based radiotracers, [64Cu]/[68Ga]HKP2201 and [64Cu]/[68Ga]HKP2202, and validate their utility for PD-L1 visualization in preclinical models. The precursor peptide HKP2201 was derived from a linear peptide ligand, CLP002, which was previously identified by phage display and showed nanomolar affinity toward PD-L1. Appropriate modification of CLP002 via PEGylation and DOTA conjugation yielded HKP2201. The dimerization of HKP2201 generated HKP2202. The 64Cu and 68Ga radiolabeling of both precursors was studied and optimized. PD-L1 expression in mouse melanoma cell line B16F10, mouse colon cancer cell line MC38, and their allografts were assayed by immunofluorescence and immunohistochemistry staining. Cellular uptake and binding assays were conducted in both cell lines. PET imaging and ex vivo biodistribution studies were employed in tumor mouse models bearing B16F10 and MC38 allografts. [64Cu]/[68Ga]HKP2201 and [64Cu]/[68Ga]HKP2202 were obtained with satisfactory radiocharacteristics. They all showed lower liver accumulation compared to [64Cu]/[68Ga]WL12. B16F10 and MC38 cells and their tumor allografts sections were verified to express PD-L1. These tracers demonstrated a concentration-dependent cell affinity and a comparable half-maximal effect concentration (EC50) with radiolabeled WL12. Competitive binding and blocking studies demonstrated the specific target of these tracers to PD-L1. PET imaging and ex vivo biodistribution studies revealed notable tumor uptake in tumor-bearing mice and rapid clearance from blood and major organs. Importantly, [64Cu]/[68Ga]HKP2202 showed higher tumor uptake compared to [64Cu]/[68Ga]HKP2201. Of note, [64Cu] labeled tracers showed longer retention in tumors than [68Ga] labeled traces, indicating advantages in the long-term tracking of PD-L1 dynamics. In comparison, [68Ga]HKP2201 and [68Ga]HKP2202 showed lower liver accumulation, enabling its great potential in the fast detection of both primary and metastatic tumors, including hepatic carcinoma. [64Cu]/[68Ga]HKP2201 and [64Cu]/[68Ga]HKP2202 are promising PET tracers for visualizing PD-L1 status. Notably, their combination would cooperate in rapid diagnosis and subsequent treatment guidance. Future assessment of the radiotracers in patients is needed to fully evaluate their clinical value.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gallium RadioisotopesMelanomaHumansAnimalsMiceB7-H1 AntigenTissue DistributionLigandsPeptidesPositron-Emission TomographyCell Line, Tumor

Stichwörter der Autor:innen

PD-L1PET imaging[64Cu]/[68Ga]HKP2201[64Cu]/[68Ga]HKP2202immune checkpoint block therapylinear peptides

Substanzen

Gallium RadioisotopesB7-H1 AntigenLigandsPeptides

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210008, China.
  • State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
  • Department of Advanced Nuclear Medicine Sciences, Institute of Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba 263-8555, Japan.
  • Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences & Research Unit of Peptide Science, Chinese Academy of Medical Sciences, 2019RU066, Lanzhou University, Lanzhou, Gans…

ORCID-Profile: Kuan Hu, Rui Wang, Ming-Rong Zhang

Förderung

  • Chinese Academy of Medical Sciences
  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science
  • National Natural Science Foundation of China
  • Beijing Nova Program
  • Nanjing Clinical Medical Center
  • Nuclear Medicine Laboratory of Mianyang Central Hospital

Zitieren

APA

Zhang, L., Zhang, S., Wu, J., Wang, Y., Wu, Y., Sun, X., Wang, X., Shen, J., Xie, L., Zhang, Y., Zhang, H., Hu, K., Wang, F., Wang, R., & Zhang, M. R. (2023). Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00382

Vancouver

Zhang L, Zhang S, Wu J, Wang Y, Wu Y, Sun X, et al. Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00382

BibTeX
@article{Zhang2023,
  author = {Zhang, Lulu and Zhang, Siqi and Wu, Jiang and Wang, Yanrong and Wu, Yuxuan and Sun, Xiaona and Wang, Xingkai and Shen, Jieting and Xie, Lin and Zhang, Yiding and Zhang, Hailong and Hu, Kuan and Wang, Feng and Wang, Rui and Zhang, Ming-Rong},
  title = {Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  doi = {10.1021/acs.molpharmaceut.3c00382}
}
Kostenlos starten →